Felix Mahfoud
Researcher Next ID · RN-026564
Researcher · Medicine
Basel, Switzerland
- Works count
- 930
- Citation count
- 65,627
- H-index
- 91
- i10-index
- 364
Research interests
Publications
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
European Heart Journal · 2025 · 10.1093/eurheartj/ehaf190
Pulsed Field or Cryoballoon Ablation for Paroxysmal Atrial Fibrillation
New England Journal of Medicine · 2025 · https://doi.org/10.1056/nejmoa2502280
Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
European Heart Journal · 2023 · https://doi.org/10.1093/eurheartj/ehad054
2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension
Journal of Hypertension · 2023 · https://doi.org/10.1097/hjh.0000000000003480
Sex differences in arterial hypertension
European Heart Journal · 2022 · https://doi.org/10.1093/eurheartj/ehac470
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial
The Lancet · 2022 · https://doi.org/10.1016/s0140-6736(22)02034-7
Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial
The Lancet · 2021 · 10.1016/s0140-6736(21)00788-1
Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk
New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2108749
Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial
The Lancet · 2020 · 10.1016/s0140-6736(20)30554-7
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
European Heart Journal · 2019 · https://doi.org/10.1093/eurheartj/ehz425
Invasive left ventricle pressure–volume analysis: overview and practical clinical implications
European Heart Journal · 2019 · https://doi.org/10.1093/eurheartj/ehz552
Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial
The Lancet · 2018 · 10.1016/s0140-6736(18)31082-1
2018 Practice guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension
Blood Pressure · 2018 · https://doi.org/10.1080/08037051.2018.1527177
2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension
Journal of Hypertension · 2018 · 10.1097/hjh.0000000000001961
Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial
The Lancet · 2018 · 10.1016/s0140-6736(18)30951-6
Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial
The Lancet · 2018 · 10.1016/s0140-6736(18)30951-6
[2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)].
PubMed · 2018 · 10.1714/3026.30245
2018 ESC/ESH Guidelines for the management of arterial hypertension
European Heart Journal · 2018 · https://doi.org/10.1093/eurheartj/ehy339
Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial
The Lancet · 2018 · 10.1016/s0140-6736(18)31719-7
Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial
The Lancet · 2017 · 10.1016/s0140-6736(17)32281-x
Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial
The Lancet · 2017 · 10.1016/s0140-6736(17)32281-x
Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials
The Lancet · 2017 · 10.1016/s0140-6736(17)30754-7
Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study
The Lancet · 2013 · 10.1016/s0140-6736(13)62192-3
Renal Hemodynamics and Renal Function After Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension
Hypertension · 2012 · https://doi.org/10.1161/hypertensionaha.112.193870
Update on Myocarditis
Journal of the American College of Cardiology · 2012 · 10.1016/j.jacc.2011.09.074
Renal Sympathetic Denervation Reduces Left Ventricular Hypertrophy and Improves Cardiac Function in Patients With Resistant Hypertension
Journal of the American College of Cardiology · 2012 · 10.1016/j.jacc.2011.11.034
Renal Denervation in Moderate to Severe CKD
Journal of the American Society of Nephrology · 2012 · 10.1681/asn.2011111062
Effect of Renal Sympathetic Denervation on Glucose Metabolism in Patients With Resistant Hypertension
Circulation · 2011 · 10.1161/circulationaha.110.991869
Comparative Evaluation of Left and Right Ventricular Endomyocardial Biopsy
Circulation · 2010 · 10.1161/circulationaha.109.924167
Current projects
No projects listed.